Targeting Profilin to Improve Blood Vessel Function in Kidney Cancer
Profilin as a Novel Target for Vascular Normalization in Renal Cancer
This study is looking at a protein called Profilin1 to see how it influences kidney cancer and its blood vessels, with the hope of finding new ways to improve treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10949012 on NIH RePORTER |
What this research studies
This research investigates the role of Profilin1, a protein involved in cell movement and growth, in the progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. The study aims to understand how Profilin1 affects the blood vessels in tumors and to explore its potential as a new treatment target. By using both genetic techniques and small molecule inhibitors, the researchers hope to find ways to normalize the blood vessels in tumors, which could improve the effectiveness of existing therapies. Patients may benefit from this research if it leads to new treatment options that overcome resistance to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who may not respond to current anti-angiogenic therapies.
Not a fit: Patients with other types of kidney cancer or those who are not diagnosed with renal cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve treatment outcomes for patients with kidney cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Gau, David Martin — University of Pittsburgh at Pittsburgh
- Study coordinator: Gau, David Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.